Not logged in.png)
Share.png)
SaveShare Save Syndecan 1 is a therapeutic target for KRAS-driven pancreatic cancer
Takeda, Mitsunobu; Yang, Zecheng; Theardy, Madeline S.; Sorokin, Alexey; Coker, Oluwadara; Chen, Shuaitong; Vien, Long T.; Bover, Laura; Ying, Haoqiang; Kopetz, Scott; Yao, Wantong Share Save A novel SDC1-targeted therapeutic antibody inhibits macropinocytosis and induces anti-tumor immunity in pancreatic cancerYang, Zecheng; Theardy, Madelaine S.; Chen, Shuaitong; Wei, Yongkun; Takeda, Mitsunobu; Wang, Xiaofei; Yao, Jun; Li, Jennifer; Park, Jangho; Zheng, Yangxi; Vien, Long T.; Bover, Laura; Ying, Haoqiang; Yao, Wantong Share Save Blockade of CD24 sensitizes pancreatic cancer to Kras inhibitorsWei, Yongkun; Liu, Minghui; Yen, Er-Yen; Yao, Jun; Nguyen, Phuoc T.; Wang, Xiaofei; Yang, Zecheng; Yousef, Abdelrahman; Pan, Dean; Jin, Yanqing; Theady, Madelaine S.; Park, Jangho; Cai, Yiming; Takeda, Mitsunobu; Vasquez, Matthew; Zhou, Yong; Zhao, Hong; Viale, Andrea; Wang, Huamin; Zhao, Dan; DePinho, Ronald A.; Yao, Wantong; Ying, Haoqiang Share Save Share Save Targeting IFNα to tumor by anti-PD-L1 creates feedforward antitumor responses to overcome checkpoint blockade resistanceLiang, Yong; Tang, Haidong; Guo, Jingya; Qiu, Xiangyan; Yang, Zecheng; Ren, Zhenhua; Sun, Zhichen; Bian, Yingjie; Xu, Lily; Xu, Hairong; Shen, Jiao; Han, Yanfei; Dong, Haidong; Peng, Hua; Fu, Yang-Xin Share Save Share Save 
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
